GT Biopharma, Inc.

greetings and welcome to the gt biopharma second quarter 2021 conference call all participants are currently in a listen-only mode following the formal presentation we'll open the call up for a question and answer session at this time i'd like to turn the conference call over to david castaneda investor relations for the company thank you you may proceed thank you operator good morning everyone and welcome to gt biopharma's second quarter 2021 conference call

Earlier this morning, we issued a press release summarizing the company's second quarter 2021 corporate updates that management will discuss on the call today. You can access the press release by going to the news and media section and then the press releases page on our website at gtbiopharma.com. GT Biopharma's following presentation and ensuing question and answer session will include statements that are or may be deemed forward-looking statements. In some cases, you can identify forward-looking statements by terminology, including anticipates, believes, can, continue, could, estimates, expects, intends, may, plans, potential, predicts, should, will, would, or is negative thereof. Other variations thereon are other comparable terminology. We operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ. could differ materially and adversely from those anticipated or implied in the forward-looking statements. You are cautioned not to place undue reliance upon such forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We direct you to our annual report on Form 10-K for the year ended December 31, 2020, our subsequent current reports on Form 8 , our quarterly report on Form 10 for the quarter ended March 31, 2021, and our other filings with the Securities and Exchange Commission. Any forward-looking statement included in this presentation speaks only as of the date hereof. Except as required by law, we do not undertake any obligation to update or revise or to publicly announce any update or revision to any of the forward-looking statements, whether as a result of new information, future events, or any other reason after the date of this presentation. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Security Litigation Reform Act of 1995. Nothing in this presentation or discussion shall be deemed an offer to purchase or sell the company's securities. Now I'd like to turn the call over to Tony Cataldo, Chairman and CEO of GT Biopharma. Tony?

Thank you, David. Good morning, everyone, and thank you for joining us. As this is GT Biopharma's first scheduled conference call, I want to thank the investment community for paying attention to the progress that GT Biopharma has demonstrated in the first half of this year. Additionally, I want to thank my entire staff for their due diligence, hard work, and the contribution they have made for an amazing first half of the year. The last fiscal quarter has been marked with numerous events and milestones reflecting tremendous success for the company. We were added into the Russell 2000, the Chicago Options Exchange, and now have enough money to execute the company's business plans for the next couple of years, approximately $40 million. We also completed our new sponsored research agreement with the University of Minnesota, headed by the TRIKE creator, Dr. Jeffrey Miller, and his team at the University of Minnesota. This will further enhance our advancement of the TRIKE platform, adding more value to GT's expanding portfolio. Our GTB 3550 TRIKE clinical trial continues to show safety in clinical results and remains well tolerated with patients who have, for all intents and purposes, been written off. The triclinical data has shown that it is remarkably effective at activating patients' own NK cells, creating persistence of NK cells, proliferation of NK cells, and making NK cells serial killers of cancer cells. Unlike our competitors, we don't need ex vivo outside manufacturing of NK cells or combination drug therapies to supplement our product. Everything the trike does is inside the body. The trike stands alone in the field of NK cell technology companies as a true monotherapy. Additionally, the trike is a toolkit for other NK cell therapies. We have data that shows that. GT will continue to update the investment community as events unfold, as well as significant corporate development milestones. I often indicate to existing and prospective investors and analysts that I believe that it is the data and not the CEO that speaks most meaningfully to the merit and potential of GT Biopharma. As such, I will now turn the call over to Martin Schroeder, our Chief Technology Officer, and Dr. Greg Burke, our Chief Medical Officer, who will recap the impressive and encouraging data we observed and reported in recent months. We will close out the call with a Q&A session. To reiterate, I'm exceedingly pleased with our advancement over the last quarter, as clearly evidenced by our concurrent share price appreciation. And with that, I'll gladly pass this call over to Martin Schroeder. Martin, take it away.